Concord Drugs Ltd
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on
approved formulations
- Market Cap ₹ 92.2 Cr.
- Current Price ₹ 70.0
- High / Low ₹ 92.5 / 49.0
- Stock P/E 87.0
- Book Value ₹ 36.8
- Dividend Yield 0.00 %
- ROCE 5.51 %
- ROE 2.57 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -9.31%
- Company has a low return on equity of 1.73% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 58.96 | 52.08 | 44.92 | 45.24 | 78.77 | |
| 53.37 | 47.51 | 40.88 | 41.10 | 74.22 | |
| Operating Profit | 5.59 | 4.57 | 4.04 | 4.14 | 4.55 |
| OPM % | 9.48% | 8.77% | 8.99% | 9.15% | 5.78% |
| 0.10 | 0.01 | 0.01 | 0.01 | 0.00 | |
| Interest | 1.68 | 1.71 | 1.87 | 2.03 | 1.71 |
| Depreciation | 1.76 | 1.63 | 1.56 | 1.43 | 1.37 |
| Profit before tax | 2.25 | 1.24 | 0.62 | 0.69 | 1.47 |
| Tax % | 28.89% | 20.97% | 25.81% | 50.72% | 28.57% |
| 1.59 | 0.99 | 0.47 | 0.34 | 1.06 | |
| EPS in Rs | 1.82 | 1.06 | 0.47 | 0.34 | 0.80 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 74% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| TTM: | 212% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 19% |
| 3 Years: | 33% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 8.74 | 9.32 | 10.00 | 10.00 | 13.18 |
| Reserves | 19.62 | 22.38 | 23.82 | 24.11 | 35.34 |
| 16.43 | 16.96 | 17.52 | 19.24 | 13.60 | |
| 11.66 | 9.57 | 7.46 | 11.80 | 12.77 | |
| Total Liabilities | 56.45 | 58.23 | 58.80 | 65.15 | 74.89 |
| 13.97 | 12.92 | 11.68 | 12.21 | 11.58 | |
| CWIP | 0.55 | 0.92 | 1.63 | 2.00 | 2.43 |
| Investments | 0.00 | 0.89 | 0.84 | 0.80 | 0.78 |
| 41.93 | 43.50 | 44.65 | 50.14 | 60.10 | |
| Total Assets | 56.45 | 58.23 | 58.80 | 65.15 | 74.89 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.77 | 1.66 | 0.79 | 3.72 | -6.77 | |
| -2.44 | -2.27 | -1.01 | -2.32 | -1.13 | |
| 1.68 | 0.62 | 0.28 | -1.43 | 8.06 | |
| Net Cash Flow | 0.01 | 0.02 | 0.07 | -0.02 | 0.16 |
| Free Cash Flow | -1.69 | 0.80 | -0.23 | 1.39 | -7.94 |
| CFO/OP | 26% | 45% | 25% | 95% | -140% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 141.52 | 110.80 | 103.44 | 109.73 | 112.97 |
| Inventory Days | 151.64 | 178.58 | 251.53 | 261.81 | 137.69 |
| Days Payable | 62.25 | 46.92 | 34.02 | 78.95 | 38.15 |
| Cash Conversion Cycle | 230.90 | 242.47 | 320.95 | 292.59 | 212.52 |
| Working Capital Days | 112.48 | 152.43 | 132.77 | 115.78 | 145.92 |
| ROCE % | 6.31% | 4.98% | 5.20% | 5.51% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure on Fixed Assets Rs. Lakhs ・Standalone data |
|
|||||||||
| Purchases from Related Parties Rs. Lakhs ・Standalone data |
||||||||||
| Sales to Related Parties Rs. Lakhs ・Standalone data |
||||||||||
| Number of Employees count ・Standalone data |
||||||||||
| Capital Work-in-Progress Rs. Lakhs ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026.
- Closure of Trading Window 25 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Copy of Newspaper publication for audited results for year ended 31st March,2026.
-
Financial Results For Year Ending 31St March,2026
29 May - Board approved FY26 audited results; standalone sales Rs 7,584.86 lakh, profit Rs 103.74 lakh.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Secretarial compliance report for FY2026 notes 27-day delay and ₹2,00,600 SOP fine for company secretary non-appointment.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
CDL is a Telangana based company which is in the business of manufacturing licensed bulk drugs and active pharmaceutical intermediates on the approved formulations. Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.